about
Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Inhalation drug delivery devices: technology update.
@en
type
label
Inhalation drug delivery devices: technology update.
@en
prefLabel
Inhalation drug delivery devices: technology update.
@en
P2093
P2860
P356
P1476
Inhalation drug delivery devices: technology update.
@en
P2093
Lucila Garcia-Contreras
Mariam Ibrahim
Rahul Verma
P2860
P304
P356
10.2147/MDER.S48888
P577
2015-02-12T00:00:00Z